EXEL : Analysis & Opinions

  1. Make Room for Exelixis in Your Portfolio

    August 12, 2015
    Discover information and analysis on the biopharmaceutical company, Exelixis, and learn what makes it a good stock to consider ...
  2. ASCO Reaffirms Why I'm Holding Exelixis

    June 5, 2015
    There are dozens upon dozens of healthcare events each and every year that highlight the latest advancements in pharmaceuticals, ...
  3. 5 Things Exelixis Management Wants You to Know

    May 22, 2015
    Just a few weeks ago, highly followed small-cap biotech stock Exelixis (NASDAQ: EXEL) reported its first-quarter earnings ...
  4. How 42 Words Completely Changed Exelixis' Report

    May 4, 2015
    Exelixis (NASDAQ: EXEL), a predominantly clinical-stage biopharmaceutical company focused on developing novel therapies ...
  5. 3 (Rough) Dates Exelixis Shareholders Need to Know

    March 30, 2015
    EXEL data by YCharts. It's incredible what a difference the simple tick of a calendar can bring for shareholders in Exelixis ...
  6. Is Exelixis Under-the-Radar Growth?

    March 6, 2015
    Exelixis was the worst-performing biotech company, with its shares collapsing after its COMET-1 study showed that  its cancer ...
  7. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  8. A Dull ASCO And The Usual Sell-Off

    June 7, 2011
    Investors shouldn't be spooked by the normal post-ASCO sell-off
  9. Four Healthcare Stocks On Fire

    November 18, 2009
    Fourth healthcare stocks that have brushed aside any potential adversity that could arise from future legislation for the ...
Trading Center